The Cancer Letter

Inside information on cancer research and drug development

ACS report: “Alarming” health disparities in preventable cancers persist as overall cancer mortality continues to fall

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Cancer mortality fell by 2.1% between 2018 and 2019, compared to a 2.4% relative decrease in the year prior, according to the American Cancer Society’s 2022 Cancer Statistics report. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Clinical Roundup

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account